Certain Drugs Distributed by the National Cancer Institute — NCD 141 | CMS Coverage Update

CMS Modified NCD 141 for NCI Group C Cancer Drugs, effective March 7, 2026. Here's what billing teams need to know.

The Centers for Medicare & Medicaid Services updated its CMS Group C drugs coverage policy under NCD 141 Medicare, which governs how Medicare covers certain cancer drugs distributed by the National Cancer Institute. This policy applies to inpatient hospital services, oral anticancer drugs, and the drugs and biologicals benefit categories. No specific CPT or HCPCS codes are listed in this policy — Group C drug billing flows through the benefit category structure, not a discrete code set.

---

Quick-Reference Table

Field	Detail Copy
Payer	CMS (Centers for Medicare & Medicaid Services)
Policy	Certain Drugs Distributed by the National Cancer Institute
Policy Code	NCD 141
Change Type	Modified
Effective Date	2026-03-07
Impact Level	Medium
Specialties Affected	Oncology, Hematology/Oncology, Inpatient Hospital Billing, Pharmacy Billing
Key Action	Verify physician NCI investigator registration and adverse event reporting compliance before billing Group C drug claims

---

CMS NCI Group C Cancer Drug Coverage Criteria and Medical Necessity Requirements 2026

NCD 141 governs Medicare coverage for a specific category of cancer drugs — Group C drugs — distributed by the Division of Cancer Treatment at the National Cancer Institute. These are not experimental drugs. The NCI designates a drug as Group C only when there is sufficient evidence of efficacy within a specific tumor type and the drug can be safely administered outside a clinical trial setting.

That distinction matters for medical necessity. Group C drugs sit in a middle tier: past the investigational stage, but not yet broadly commercially available in all cases. Medicare's coverage policy here is actually more permissive than it is for typical investigational drugs — but only when the NCI's four eligibility requirements are fully satisfied.

Here's where the medical necessity argument lives. A/B Medicare Administrative Contractors (MACs) may assume coverage for a Group C drug and the related hospital stay if all other applicable Medicare coverage requirements are met. That's a conditional presumption, not a blanket guarantee. If your claim raises flags, the MAC can refer the case to the Quality Improvement Organization (QIO) for resolution.

Prior authorization is not explicitly required under NCD 141. But that doesn't mean your claims are low-risk. The NCI compliance requirements function as de facto prior authorization conditions — if the physician isn't registered, if the indication is off-label relative to NCI guidelines, or if adverse reactions haven't been reported, coverage evaporates.

---

CMS NCI Group C Drug Physician Eligibility and NCI Compliance Requirements

This is the core of NCD 141, and it's where billing teams most often get into trouble. Coverage for Group C drug claims depends entirely on whether the administering physician meets four NCI requirements.

Requirement 1: NCI investigator registration. The physician must be registered with the NCI as an investigator by completing FDA Form 1573. No registration, no coverage — full stop. Before you submit any claim tied to a Group C drug, confirm this registration is in place and documented in the record.

Requirement 2: Written drug request. The physician must submit a written request to the NCI specifying the disease being treated. This isn't a clinical note — it's a formal written request to the NCI's Investigational Drug Branch. Your documentation checklist should include a copy or confirmation of this request.

Requirement 3: Indication must match NCI guidelines. Group C drug use is limited to the indications outlined in the NCI's guidelines for that specific drug. Off-label use — even for a related cancer type — does not qualify. This is the most common source of claim denial under this policy.

Requirement 4: Adverse reaction reporting. All adverse reactions must be reported to the Investigational Drug Branch of the Division of Cancer Treatment. If your facility administers a Group C drug and an adverse event occurs, that report needs to go out. Failure to report doesn't just create a regulatory problem — it undermines the coverage presumption for future claims.

The reimbursement path only stays open when all four of these boxes are checked. Miss one, and you're looking at a coverage denial your MAC can justify without escalation.

---

Coverage Indications at a Glance

---

CMS NCI Group C Cancer Drug Billing Guidelines and Action Items 2026

The effective date of March 7, 2026 means this policy is live now. If your facility treats oncology patients with NCI-distributed drugs, these steps need to happen immediately.

Copy Action Items

If your facility handles a significant volume of oncology inpatient billing and you're not certain how this policy applies to your current mix of NCI-distributed drugs, talk to your compliance officer before submitting claims under NCD 141.

---

CPT, HCPCS, and ICD-10 Codes for NCI Group C Drugs Under NCD 141

Covered CPT/HCPCS Codes

This policy does not list specific CPT or HCPCS codes. Group C drug billing routes through the applicable Medicare benefit categories — Drugs and Biologicals, Inpatient Hospital Services, and Oral Anticancer Drugs — rather than a discrete code set enumerated in NCD 141. Your coding team should apply the standard drug administration and pharmacy codes appropriate to the specific drug and care setting, consistent with your MAC's billing guidelines.

Key ICD-10-CM Diagnosis Codes

No ICD-10 codes are specified in NCD 141. Diagnosis codes should reflect the specific tumor type and indication that aligns with NCI guidelines for the Group C drug being administered. The indication documented in the claim must match the indication in the physician's written NCI drug request.

---

What This Policy Change Actually Means for Billing Teams

The practical reality of NCD 141 is that it creates a coverage framework that is more favorable than typical investigational drug policies — but only for teams that execute on the compliance requirements. The MAC's presumption of coverage is a real billing benefit. It means you don't have to fight to establish that a Group C drug is medically necessary in the traditional sense — the NCI's classification process does that work for you.

The risk is entirely on the process side. A physician who isn't registered with the NCI, a written drug request that was never submitted, an adverse event that was never reported — any one of these turns a presumptively covered claim into a denial. And because no specific CPT or HCPCS codes are listed in the policy, your billing team can't catch these issues through a code-level edit. The catch has to happen at the documentation review stage.

This is a policy where your clinical and billing teams genuinely need to be in sync. The billing guidelines live in the administrative compliance requirements, not in the code structure. Build that into your pre-submission workflow.

---